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Abstract 
Cannabinoids (CB) show promise as neuroprotectants with some agents 
already licensed in humans for other conditions. We systematically reviewed 
CBs in pre-clinical stroke to guide further experimental protocols. We selected 
controlled studies assessing acute administration of CBs for experiment 
stroke, identified through systematic searches. Data were extracted on lesion 
volume, outcome and quality; analysed using random effects models; results 
are expressed as standardised mean difference (SMD) with 95% confidence 
intervals [CI]. 144 experiments (34 publications) assessed CBs on infarct 
volume in 1473 animals. CBs reduced infarct volume in transient (SMD -1.41, 
[95% CI -1.71,-1.11], p<0.00001) and permanent (-1.67 [-2.08,-1.27], 
p<0.00001) ischaemia and in all subclasses: endocannabinoids (-1.72 [-2.62,-
0.82], p=0.0002), CB1/CB2 ligands (-1.75 [-2.19,-1.31], p<0.00001), CB2 
ligands (-1.65 [-2.09,-1.22], p<0.00001), cannabidiol (-1.20 [-1.63,-0.77], 
p<0.00001), Δ9-tetrahydrocannabinol (-1.43 [-2.01,-0.86], p<0.00001) and HU-
211 (-2.90 [-4.24,-1.56], p<0.0001). Early and late neuroscores significantly 
improved with cannabinoid use (-1.27 [-1.58,-0.95], p<0.00001; -1.63 [-2.64,-
0.62], p<0.002 respectively) and there was no effect on survival. Statistical 
heterogeneity and publication bias was present, median study quality was 4 
(range 1-6/8). Overall, CBs significantly reduced infarct volume and improve 
functional outcome in experimental stroke. Further studies in aged, female 
and larger animals, with other co-morbidities are required. 
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Introduction 
Components of the endocannabinoid system (ECS) are altered following 
ischaemic stroke. The expression of CB1 and CB2 receptors are upregulated 
in the rat brain following cerebral ischaemia,1, 2 indicating that the ECS may 
play an important role in the endogenous response to stroke, though the 
relevance of these changes are not known. Human and animal in vivo data 
have shown increases in neurological levels of anandamide (AEA), 
oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), with 2-
arachidonoylglycerol (2-AG) levels either unchanged or increased.3-8 Pre-
clinical stroke studies have derived neuroprotective qualities from a range of 
approaches to manipulating the ECS. For example, CB2 ligands can modify 
the post-stroke inflammatory response, and CB1 activation can initiate a 
chemical hypothermia, with both processes resulting in a decrease in stroke 
infarct volume. 9, 10 Activation of CB2 receptors has only demonstrated 
protective effects and the role of CB1 activation is less clear with studies 
demonstrating efficacy of both CB1 agonists and antagonists.11, 12 
Cannabinoids can be divided into three categories: endocannabinoids, 
phytocannabinoids and synthetic cannabinoids. AEA and 2-AG (both CB1/2 
agonists) are the best studied endocannabinoids, but other chemically similar 
compounds have been suggested as endocannabinoids or endocannabinoid-
like compounds, including OEA, PEA, lauroylethanolamide and 
linoleoylethanolamide. Endocannabinoids also display activity at non-CB1/2 
receptor sites, including TRPV1, PPARα/γ, 5HT1A and GPR55.13  
Phytocannabinoids are derived from the cannabis plant, a unique source of 
over 60 different compounds, with Δ9-tetrahydrocannabinol (THC) and 
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cannabidiol (CBD) already in clinical use to treat spasticity in multiple 
sclerosis (Sativex). THC is a partial agonist for CB1 and CB2 receptors, whilst 
CBD displays low affinity for CB receptors.14 Synthetic cannabinoid 
compounds have been developed, some of which exhibit high potency at CB1 
(arachidonyl-2’-chloroethylamide) or CB2 (JWH-133, O-1966 and O-3853) 
receptors, activate both CB1/2 (CP 55,940, HU-210, TAK-937 and WIN 
55,212-2), or activate non-CB receptors (e.g. HU-211, a proposed NMDA 
antagonist).  
Given the accumulating preclinical evidence for the use of cannabinoids in 
stroke, as well as the expansion in the use of cannabinoid-based medicines in 
other disorders, a systematic review of the currently available preclinical 
literature is warranted. Whilst it is clear there are many studies describing the 
benefit of administering cannabinoids for experimental stroke, a number of 
unanswered questions remain before the transition is made into ‘bedside’ 
testing. It is unclear as to whether the optimal time of administration and dose 
of the various cannabinoid classes have been established, and whether the 
body of evidence is reliable and consistent. The aim of this study, therefore, is 
to systematically review and meta-analyse the effects of exogenous 
cannabinoid administration on infarct volume, functional outcome and survival 
in animal models of ischaemic stroke. 
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Methods 
Search Criteria 
Experimental (non-human) studies in evaluating the effect of cannabinoids on 
focal acute stroke were searched up to December 2013 in PubMed, Medline, 
Embase, ScienceDirect, and Web Of Science. Search keywords included 
were ‘stroke,’ ‘ischaemia,’ ‘cannabinoid,’ ‘cannabidiol,’ ‘delta-9-
tetrahydrocannabinoid,’ ‘WIN 55,212-2,’ ‘2-Arachidonoy glycerol,’ 
‘endocannabinoids,’ ‘CB1 receptors,’ and ‘CB2 receptors.’ References from 
included studies and conference proceedings were also searched. There was 
no protocol per se, although pre-specified exclusion criteria were used to 
prevent bias and studies were included if the following were met: (i) a focal 
ischaemic stroke model, not global; (ii) treatment was given for an acute 
model (within 48 hours), not chronic; (iii) only cannabinoid ligands were given; 
(iv) there was a control group; (v) there were measures of infarct size, 
functional outcome or survival; and (vi) data was from an original article, not a 
review article. If an article was only available as an abstract it was not 
included.  
 
Data acquisition 
Data on total infarct size, measured in percentage (%) or volume (mm3) were 
extracted from included papers. Volumes corrected for oedema were chosen 
instead of uncorrected data. When all data was not available, authors were 
contacted for the exact numbers of animals used in each group for each 
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experiment. If authors were unable to provide necessary information, the 
lowest number of animals within the range given was used. The Grab 
application (version 1.5) was used to obtain values from figures given in 
published articles if no values were stated within the text. Similarly, 
information on vital status, weight (grams), Rotarod test (time spent on 
Rotarod expressed in seconds or percentage compared to baseline) and 
neurological score were collected. If published articles used multiple groups 
(e.g., to assess time response relationships) with one control group, then the 
number of animals per control group was divided into the number of 
comparison groups. Since different procedures were used in different 
experiments, the total dose of drug given throughout a complete experiment 
was taken instead of a single dose. When drugs were given at more than one 
point of time, the earliest time of administration was used. 
 
Quality 
Methodological quality was assessed using an eight-point criteria derived from 
STAIR 15, as used previously, 16, 17 with 1 point given to evidence of the 
following: presence of randomisation, monitoring temperature throughout the 
experiment, masked outcome measurement, assessment of outcome at days 
1-3, assessment of outcome at days 7-30, assessment of outcome other than 
just infarct size, dose-response relationship conducted, and therapeutic time 
window relationship of a particular agonist conducted.  
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Data analysis 
Data were grouped before analysis by (i) model type (permanent or transient 
ischaemia); (ii) species; (iii) time to treatment; (iv) total dose and (v) 
cannabinoid type. Data from each of these groups were analysed as forest 
plots using the Cochrane Review Manager software (version 5.2) and Stata 
(version 11), as used in previous animal meta-analyses.17 Since 
heterogeneity was expected between study protocols (different species, 
stroke models, dose, time), random effect models were used. The results of 
continuous data are expressed as standardised mean difference (SMD), with 
95% confidence intervals (CI), which allows data measured on different scales 
and in different species to be merged. The results of binary data (survival) are 
expressed as odds ratios (OR) with 95% CI. Studies were weighted by 
sample size and statistical significance was set at p<0.05. PRISM 6 
(GraphPad) was used to compare the dose- and time-response relationship 
between drug classes. Infarct volume data acquired can be accessed at 
http://dx.doi.org/10.6084/m9.figshare.1228070. 
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Results 
Design of the studies 
The initial search for studies identified 101 relevant publications. Once the 
pre-specified inclusion criteria were applied, a total of 34 publications were 
chosen for analysis (Figure 1, Table 1). These came from 18 laboratories in 9 
countries (USA, Israel, Italy, Japan, Spain, Denmark, Germany, UK and 
China). Studies were excluded if they examined global ischaemia, neonatal 
animals, did not measure infarct volume or functional outcome, did not 
administer a cannabinoid receptor ligand, were review articles (not original 
articles), where induction of injury was by methods other than 
ischaemia/reperfusion or if the data was unobtainable.  
19 of 34 publications studied 786 rats 5, 10, 18-34 and 14 studied 673 mice;3, 9, 11, 
12, 35-44 1 article studied rats and primates.45 24 articles examined greater than 
1 experimental paradigm (total number of experiments 144). Transient 
ischaemic models were used in 21 publications, vessel occlusion time ranging 
between 30 minutes to 4 hours. Permanent models of ischaemia were used in 
13 articles (photothrombotic n=2). Drugs were administered intravenously 
(n=17) or via the peritoneum (n=16), and one study used the oral route.44 
Time of administration ranged from pre-ischaemia up to 5 days post middle 
cerebral artery occlusion (MCAo). Median study quality was 4 (range 1-6).  
 
Infarct volume 
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Overall, administration of cannabinoid receptor ligands reduced infarct volume 
in comparison to vehicle; standardised mean difference, SMD, -1.49, 95% 
confidence interval CI, -1.73 to -1.25, p < 0.00001 (Figure 2, Table 2). If we 
only include the 18 publications (75 experiments, 767 animals) reporting 
absolute lesion volume in the analysis, the weighted mean difference (WMD) 
between groups was -28.3 mm3 (95% CI -32.4, -24.2, p<0.00001) in favour of 
cannabinoids; equivalent to a SMD of -1.27 (95% CI -1.58, -0.97, p<0.00001). 
Infarct volume was significantly reduced in rats and mice, SMD -1.75, (95% CI 
-2.15 to -1.35, p < 0.00001) and -1.34 (95% CI -1.61 to -1.06, p < 0.00001) 
respectively. The only study involving primates revealed non-significant infarct 
volume reduction upon administration of TAK-937, a CB1/CB2 receptor ligand 
(SMD -0.55, 95% CI -1.62 to 0.53, p = 0.32).45  
 
When grouped by drug class, synthetic agonists (mixed CB1/CB2 ligands 
(p<0.00001), CB2 ligands (p<0.00001), HU-211 (p<0.0001)), 
phytocannabinoids (THC and CBD (both p<0.00001)) and endocannabinoids 
(p=0.002) all reduced infarct volume significantly (see Table 2). The 
breakdown by individual compound can be seen in Figure 2; the most 
profound infarct volume reduction is seen with HU-210, a synthetic CB1/CB2 
ligand (n=8 experiments, 80 animals 10) (SMD -3.52, 95% CI –5.34 to -1.71). 
Methanandamide, lauroylethanolamide and linoleoylethanolamide were all 
neutral in their effect, whereas AEA (n=3, 28 animals) showed borderline 
significant infarct volume reduction (SMD -0.78, 95% CI –1.64 to 0.08, 
p=0.07).  
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Individual studies of the CB1 antagonist SR141716 had a neutral effect on 
lesion volume except when used at a very high dose (20 mg/kg 11) leading to 
a significant reduction in lesion size (SMD -5.59 [95% CI -9.69, -1.49], 
p=0.008). Trends to harm were seen using the CB2 antagonist SR144528 
(SMD 0.96, 95% CI -0.32 to 2.24 p=0.14).  
There was significant statistical heterogeneity (I2 56%, p<0.00001, Figure 2) 
in the all studies analysis. 
 
Drug dose 
The effect of drug class dose on infarct volume was analysed to help establish 
whether there was a dose-response relationship with infarct volume reduction 
for each class of cannabinoid (Figure 3).  
CB1/CB2 agonists were significantly effective at numerous doses and showed 
a bimodal distribution of maximum effect with peaks at 45 mcg/kg (HU-210, 
SMD -4.16, 95%CI -7.17 to -1.16, p=0.007, n=5 experiments, 50 animals) 10 
and 5 mg/kg (WIN 55,212-2, SMD -6.0, 95%CI -9.04 to -2.95, p=0.0001, n=1, 
13 animals,25 Figure 3a). Significant statistical heterogeneity was present (I2 
63%, p<0.00001). 
CB2 ligands were tested between total doses 0.5 mg/kg and 10 mg/kg with 
peak effect at 5 mg/kg (JWH-133 and O-1966, SMD -2.38, 95%CI -4.06 to -
0.71, p=0.005, n=5, 37 animals,41, 42 Figure 3b). There was no significant 
statistical heterogeneity. 
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THC significantly reduced infarct volume at two doses, 10 and 20 mg/kg 
(SMD -0.95, 95%CI -1.92 to -0.02, p=0.05, n=3, 27 animals; and SMD -2.41, 
95%CI -3.29 to -1.53, p<0.00001, n=6, 59 animals, respectively; Figure 3d). A 
dose-response relationship was observed with CBD, the greatest lesion 
volume reduction using 6 mg/kg (SMD -1.89, 95%CI -2.7 to -1.07, p<0.00001, 
n=6, 57 animals 36, 38, 39). No effect was seen at the greater dose of 10 mg/kg 
(n=1, 9 animals),3 Figure 3e.  
Peak effect with administration of endocannabinoids was seen at 20 mg/kg 
(SMD -4.28, 95%CI -6.85 to -1.71, p=0.001, n=2, 16 animals 24, 44) with 
significant but less potent effects seen with 30 and 40 mg/kg (Figure 3f). 
Statistical heterogeneity was evident in the endocannabinoid analysis (I2 78%, 
p<0.00001) but not for THC and CBD. 
 
Time of administration 
CB1/CB2 agonists, assessed up to 8 hours post stroke, revealed a gradual 
decline in effect size over time, with significant effects seen up to 4-5 hours 
after insult (Figure 4a). A similar pattern was seen for endocannbinoids but 
with loss of significant effect as soon as 2-3 hours post stroke (Figure 4f). HU-
211 produced significant infarct volume reduction as late as 6 hours post ictus 
(Figure 4c). Both CBD (up to 6 hours) and THC (up to 4 hours) demonstrated 
trends to infarct reduction with later administration but there were too few 
studies to produce significant values at these later time points (Figures 4d and 
4e); 17 of 23 experiments using CBD (and 11 of 13 for THC) administered the 
drug before stroke onset. 
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Functional outcome and survival 
Early neurological outcome improved significantly when evaluated in 55 
experiments (590 animals), SMD -1.27 95% CI -1.58 to -0.95, p<0.00001. 
Late neurological impairment was only assessed in 8 experiments (126 
animals) but this still resulted in a significantly improved outcome (p=0.002, 
Table 2). No effect was seen on survival in 7 experiments (154 animals). 
 
Quality 
10 of 34 publications utilised randomisation in their design, 4 reported blinding 
of outcome assessments, 21 monitored temperature during surgery, 33 
measured outcome at 1-3 days and 4 at 7-30 days, 28 measured outcomes 
other than lesion size, 12 assessed a time window for administration and 16 
established dose response effects.    
There was no relationship between quality score and lesion volume effect size, 
Spearman’s rho co-efficient -0.113, p=0.18. Likewise, there were no 
significant differences in effect size when comparing individual components of 
the scale such as randomisation and blinding of outcome assessment. 
 
Publication bias 
Begg’s funnel plots were visually analysed to determine the presence or 
absence of publication bias. For all studies, significant bias was present 
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(Egger’s statistic p<0.001, Figure 5H46). Significant bias was present in the 
subgroups CB1/2 agonists (p<0.001, Figure 5A), CB2 agonists (p=0.023, 
Figure 5B), HU-211 (p<0.001, Figure 5C), and endocannabinoids (p=0.038, 
Figure 5F).
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Discussion 
This extensive meta-analysis has determined that cannabinoids significantly 
reduce infarct volume in both transient and permanent models of ischaemia, 
and improve both early and late functional outcome. Almost twice as many 
animals were studied in transient (n=945) than permanent (n=519) models 
and greater infarct volume reductions were seen in permanent models (SMD -
1.67 versus -1.41). HU-210, a CB1/CB2 agonist, demonstrated the greatest 
infarct volume reduction and the CB1/CB2 agonist group were effective when 
administered as late as 5 hours post stroke onset. HU-211, a proposed NMDA 
antagonist and enantiomer of HU-210, was effective up to 6 hours after onset.  
The mechanisms of action responsible for the effects of cannabinoids in the 
pre-clinical setting are multiple but not well understood or always explored 
within these studies. CB1 receptors are primarily located in the central 
nervous system, with activation known to decrease excessive glutamate 
release, 38 allied excitotoxicity 47 and enhance cerebral blood flow.48 THC,36 
TAK-937,33 WIN 55212-2 19 and HU-210 10 are protective through CB1 
mediated hypothermia, an effect abolished by warming. CB2 receptors are 
expressed predominantly by cells of the immune system but they also display 
CNS presence, in particular, microglial cells activated during the course of 
inflammation express CB2 receptors.49 Activation of CB2 receptors results in a 
decrease in the release of pro-inflammatory cytokines, neutrophil recruitment 
9, 41 and leukocyte adhesion to cerebral vessels.43 
Cannabinoid induced neuroprotection is also likely to be mediated through 
other receptor targets, though the only proven sites include CB1,36, 38 CB2 9, 11, 
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41 and 5HT1A.3, 39 For example, the effects of CBD are not inhibited by CB1, 
CB2 or TRPV1 (transient receptor potential cation channel subfamily V1, or 
capsaicin receptor) antagonism, but its ability to decrease infarct volume and 
enhance cerebral blood flow appear to be mediated, at least in part, through 
5HT1A.3, 39 Other mechanisms, such as anti-inflammatory effects, are yet to be 
linked to a particular target site, and other known cannabinoid target sites of 
action such as TRPs and PPARs (peroxisome proliferator-activated receptors) 
require further exploration. The endocannabinoid PEA is associated with 
reduced cell death, oedema and inflammation,18 and OEA is thought to 
mediate its infarct-reducing effects through PPARα, as the protective effects 
of OEA were absent in PPARα-/- mice 40 and inhibited by a PPARα 
antagonist.44 
Our systematic review has highlighted many deficiencies in the existing 
literature that warrant further investigation. It is not apparent that CB2 
antagonists have been tested against mixed CB1/CB2 ligands, which is 
important considering that CB2 activation is a potential therapeutic target. 
Furthermore, expression of CB2 receptors decreases in the first 3 hours after 
MCAo and then gradually increases by 24 hours.11 It may, therefore, be of 
benefit to stimulate CB2 at later time points; our time-to-treatment analysis 
only showed a trend to infarct volume reduction at 2-3 hours with CB2 
agonists and there were no experiments extending drug delivery beyond 3 
hours. In this review, other cannabinoids show promise with later 
administration causing significant infarct volume reduction, including CB1/CB2 
receptor agonists (up to 5 hours) and HU-211 (up to 6 hours). CBD may also 
be beneficial at later time points with trends to reduce infarct volume as late 
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as 6 hours but there were too few studies to demonstrate a significant effect; 
in one study, animal survival was significantly increased even when CBD was 
administered 3 days following stroke.35 
The optimal dose of administration for each drug class also remains unclear. 
It was generally seen that higher doses resulted in a greater degree of infarct 
volume reduction. Furthermore, questions are raised with regards to the role 
of CB1 antagonism; CB1 agonists mediate their positive effects through the 
various mechanisms described but CB1 antagonism with SR141716 used at a 
high dose (20 mg) also appeared to be beneficial (it was neutral at lower 
doses). The mechanisms of such an effect are not understood. If CB1 
agonism were detrimental in stroke, the effects of the mixed CB1/CB2 agonists 
should be less than that of the CB2 specific drugs, although this was not 
observed. It is more likely that beneficial effects of the CB1 antagonist at high 
doses are off-target effects, non-CB1 mediated responses, as previously 
suggested for SR141716A.50 
Further data is also required exploring the effects of cannabinoids in stroke in 
animals with other co-morbidities, as would occur in humans. For example, 
only one group have also observed the effects of cannabinoids (TAK-937) in 
aged and female rats and larger species.28, 45 Moreover, TAK-937 is the only 
compound that has examined co-administration with thrombolysis,28 essential 
with regards to safety since some neuroprotectants can enhance the risks of 
rtPA associated haemorrhage.51 Hypertensive rats have been studied using 
HU-211 only, 26, 27, 34 but largely data is absent on the effects of cannabinoids 
in animals with co-morbidities relevant to stroke.52 It is also clear that 
neurological assessments of functional outcome at later time points are 
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lacking with only 8 of 144 experiments (HU-211, CBD, TAK-937) measuring 
late neuroscores.26, 35, 45 This is important considering the outcomes in future 
clinical trials will be related to functional outcome and safety.  
There are limited data regarding the safety of cannabinoids in humans and 
none in the stroke population. Sativex, licenced for use in treating spasticity 
secondary to Multiple Sclerosis, containing THC and CBD in a 1:1 ratio 
(2.7mg:2.5mg per 100µl), can commonly cause dizziness, depression, 
euphoria, gastro-intestinal upset and altered appetite; uncommonly it causes 
palpitations, tachycardia, hallucinations and suicidal ideation.53 In a 14-week 
open label study of 339 patients, 5% discontinued Sativex secondary to 
treatment related side effects.54 The psychotropic side effects appear to be 
mediated through THC CB1 stimulation and studies using CBD alone, 
however, indicate that it is very well tolerated; in 3 small studies CBD did not 
affect heart rate and blood pressure using a single 600mg dose,55-57 and in 
regular use for epilepsy (200-300mg), no specific adverse events were 
reported (4 randomised studies of poor quality, total n=48).58  
Our paper has a number of limitations affecting interpretation of results, 
issues that confound many meta-analyses. First, significant heterogeneity is 
present secondary to the variability in design of individual studies. This is 
accounted for, in part, by using a random effects model of analysis. Moreover, 
further heterogeneity is introduced by organising compounds into subgroups; 
although we have classed the drugs by mechanisms of action, it is likely that 
many will act on other target sites not identified and therefore statements on 
efficacy could be an under- or over-estimate. Second, caution must also be 
taken due to the presence of significant publication bias;59 our search strategy 
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may have missed publications in less well known journals; the non-inclusion 
of some studies means that the estimated treatment effects could be 
inaccurate. Third, the results also depend on study quality which can also 
impact report precision; 10 of 34 publications utilised randomisation in their 
design and only 4 reported blinding of outcome assessments. The impact of 
various quality items on reported efficacy has been previously assessed;60 the 
presence or absence of randomisation to a treatment group, blinding of drug 
allocation and blinding of outcome assessments were the most powerful 
determinants of outcome. In contrast, this review did not find any relationship 
between study quality and efficacy, even when individual components of 
quality were analysed. However, the absence of some of the parameters in 
our ‘quality’ score does not necessarily mean that the experiment was carried 
out to a poor standard; for example, evaluating timing of outcome 
assessments is simply expanding the cohort of evidence rather than 
improving the study quality. Second, it may be that some studies did not 
report specific components such as randomisation, which may explain why we 
found no relationship between quality and efficacy. Fourth, many publications 
would often use an inadequate number of animals in the control arms of the 
experiments involving multiple comparisons (e.g. comparing several dose-
arms to one control group) resulting in smaller control groups in the meta-
analysis (it is important not to count the control animals more than once). 
Moreover, the small group sizes produce imprecise estimates of the variance 
and, therefore, the SMD. SMD, and not weighted mean difference (WMD), 
was used in order to merge different scales measuring the same parameter; 
of 34 publications, 14 measured infarct volume as percentage and 18 used 
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absolute volume (mm3). Interpretation of SMD is less intuitive but it has 
allowed us to include significantly more studies within the analysis.  
The failure of multiple neuroprotective agents to be translated into the clinical 
setting has been extensively highlighted in the literature, 15, 61 hence, 
evaluating pre-clinical data thoroughly and systematically before progressing 
to designing human clinical trials is of great importance. Indeed, before 
moving novel experimental ideas into clinical trials, it is proposed that multi-
centre phase III-type preclinical studies are performed 
(www.dcn.ed.ac.uk/multipart). There are no previous clinical trials using 
cannabinoids in stroke but positive data from trials using cannabinoids in 
other neurological diseases already exist.62 The pleiotropic effects of 
cannabinoids on the ischaemic penumbra and cerebral vasculature following 
stroke, combined with their excellent tolerability, make them promising 
candidates for future treatment.  
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Titles and Legends to Figures  
 
Figure 1: Record identification process. 
 
Figure 2: Forest plot of the effects of cannabinoids on experimental infarct 
volume subdivided by drug treatment. Each subgroup is ordered by increasing 
dose. Time of administration is given where ‘pre’ represents administration 
before stroke onset and ‘h’ the number of hours after. 
 
Figure 3: The effect of cannabinoid drug dose on experimental infarct volume 
subdivided by drug class. The standardised mean difference (SMD) in infarct 
volume is plotted against log [dose] for each drug subgroup (a-g). Error bars 
represent 95% confidence intervals (CI) and values are not significant where 
they cross zero. 
 
Figure 4: The effect of time of administration on experimental infarct volume 
subdivided by drug class. The standardised mean difference (SMD) in infarct 
volume is plotted against time of administration for each drug subgroup (a-f). 
Error bars represent 95% confidence intervals (CI) and values are not 
significant where they cross zero. 
 
Figure 5: Funnel plots for all studies (a) and each cannabinoid subgroup (b-h) 
evaluating publication bias. Standard error of the standardised mean 
difference (SE (SMD), y-axes) for each study is plotted against its effect size 
(SMD, horizontal axes)).
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Table 1. Description of included studies 
 
Study Species  Model Drug Total Dose Route Time of administration Unit of infarct 
volume 
Time of 
assessment 
STAIR 
score 
Ahmad 2012 18 Wistar rats T 2 h PEA 10 mg/kg i.p. 1 and 6 h post mm3 24 h 4 
Bonfils 2006 19 Wistar rats T 0.5 h WIN 55,212-2 9 mg/kg/h i.v. 0.5 h post until 22 h mm3 7 d 2 
Berger 2004 20 Wistar rats P* SR141716 1 mg/kg i.v. 30 min post-onset mm3 5 h 3 
Belayev 1995a 21 Wistar rats T 1.5 h HU-211 4 mg/kg i.v. 70 min post-onset mm3 72 h 2 
Belayev 1995b 22 Wistar rats P  HU-211 4 mg/kg i.v. 30 min post-onset n/a n/a 2 
Garg 2010 23 
Experiments 1-4 
 
Spr-Dawley rats 
 
T 1.5 h 
 
PEA 
 
10 mg/kg 
 
i.p. 
 
Pre, 0, 2 or 3 h post 
 
% 
 
24 h 
 
Garg 2011 24 
Experiment 1 
Experiment 2-3 
 
Spr-Dawley rats 
 
T 1.5 
 
Lauroylethanolamide 
Linoleoylethanolamide 
 
10 mg/kg 
10 or 20 mg/kg 
 
i.p. 
 
Pre onset 
 
% 
 
24 h 
 
4 
Hayakawa 2004 36 
Experiment 1 
Experiment 2 
 
ddY mice 
 
 
T 4 h 
 
CBD  
THC 
 
6 mg/kg 
20 mg/kg 
 
i.p. 
 
Pre-onset 
 
mm3 
 
24 h 
 
3 
Hayakawa 2007a 12 ddY mice T 4 h THC 20 mg/kg i.p. Pre-onset mm3 24 h 3 
Hayakawa 2007b 39 
Experiment 1-3 
Experiment 4-6 
Experiment 7 
 
ddY mice 
 
 
T 4 h 
 
THC 
CBD 
SR141716 
 
2, 6, 20 mg/kg 
0.2, 2, 6 mg/kg 
1 mg/kg 
 
i.p. 
 
Pre-onset 
 
mm3 
 
24 h 
 
3 
Hayakawa 2007c 38          
Experiment 1-3 ddY mice T 4 h CBD 0.2, 2, 6 mg/kg i.p. Pre-onset mm3 24 h 5 
Experiment 4-6   THC 2, 6, 20 mg/kg  Pre-onset  24 h  
Experiment 7&9    CBD 6 mg/kg  Pre-onset  24&72 h  
Experiment 8&15   THC 20 mg/kg  Pre-onset  24&72 h  
Experiment 10-14   CBD 3 mg/kg  Pre-onset, 3 h post, at 
reperfusion, 1 h or 2 h post-
reperfusion 
 24 h  
Experiment 16-18 
Experiment 19 
  THC 
SR141716 
10 mg/kg 
1 mg/kg 
 Pre-onset, 3h, reperfusion  
Pre-onset 
 24 h  
Hayakawa 2008 37          
Experiment 1-3 ddY mice T 4 h CBD 0.1, 1, 3 mg/kg i.p. Pre-onset mm3 24 h 4 
Experiment 4   SR141716 1 mg/kg      
Hayakawa 2009 35          
Experiment 1-3 ddY mice T 4 h CBD 3 mg/kg  i.p. Days 1, 3 or 5 n/a - 4 
Hu 2010 25          
Experiment 1-3 Spr-Dawley rats T 2 h WIN 55,212-2 1, 3 or 5 mg/kg i.p. Pre-onset 1, 3 or 5 days % 72 h 6 
Lavie 2001 26          
Experiment 1-3 Hypertensive rats P HU-211 4.5 mg/kg i.v. 1, 3 or 6 h post-onset % 24 h 6 
Experiment 4-6      1, 3 or 6 h post onset  30 d  
Leker 1999 27 Hypertensive rats P HU-211 4 mg/kg i.v. 1 h post-onset % 24 h 2 
Leker 2003 10          
Experiment 1-4 Sp-Dawley rats P HU-210 5, 10, 30, 45 µg/kg i.v. 1 h post-onset % 72 h 5 
Experiment 5-8    45 µg/kg  1, 2, 4, or 6 h post-onset    
Mishima 2005 3          
Experiment 1-4 ddY mice T 4 h CBD 0.2, 2, 6, or 20 mg/kg i.p. At pre-onset mm3 24 h 4 
Experiment 5-6   Abnormal CBD 6 or 20 mg/kg      
Experiment 7-8   Anandamide 6 or 20 mg/kg      
Experiment 9-10   Methanandamide 6 or 20 mg/kg      
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Muthian 2004 5          
Experiment 1-3 Wistar rats T 2.5 h WIN 55,212-2 0.1, 0.3, or 1 mg/kg i.v. 5 min pre-onset mm3 24 h 5 
Experiment 4-6   SR141716 0.1, 0.3, or 1 mg/kg      
Experiment 7   LY320153 6 mg/kg      
Murakami 2013 28 
Experiment 1-6 
Experiment 7-8 
Experiment 9 
 
Rats 
 
Aged rats 
 
P 
P* 
P* 
 
TAK-937 
 
30, 100 mcg/kg/h 
 
100 mcg/kg/hr 
 
i.v. 
 
3, 5 or 8 h post, until 24 h  
1 h post until 24 h 
1 h post until 24 h 
 
% 
 
48 h 
 
4 
Murikinati 2010 9 C57BL/6 mice P JWH-133 1 mg/kg/day i.v. 4 hours pre-onset mm3 3 d 2 
Nagayama 1999 29          
Experiment 1-4 
Experiment 5 
Spr-Dawley rats P WIN 55,212-2 
SR141716 
1 mg/kg 
1 mg/kg 
i.p. 30 min pre-, 30, 60, or 120 
min post- 
mm3 24 h 4 
Schomacher 2008 30          
Experiment 1-2 Wistar rats T 1.5 h PEA 30 or 10 mg/kg i.p. 30 min post-onset mm3 24 h 5 
Experiment 3   Anandamide 10 mg/kg      
Sun 2007 40 C57BL/6 Mice T 2 h OEA 10mg/kg/day i.p. -3,-2 & -1 days pre-onset mm3 48 h 1 
Sun 2013a 31          
Experiment 1-2 Spr-Dawley rats P WIN 55,212-2 1 or 9 mg/kg i.v. 2 h post-onset % 24 h 5 
Sun 2013b 32 
Experiment 1-5 
Experiment 6-7 
 
Spr-Dawley rats 
 
P 
 
WIN 55,212-2 
SR141716 
 
 
1, 3 or 9 mg/kg 
1 or 2 mg 
 
i.v. 
 
2 h 
 
% 
 
24 h 
 
4 
Suzuki 2012a 45          
Experiment 1-4 Spr-Dawley rats T 2 h TAK-937 3, 10, 30 or 100 µg/kg i.v. At reperfusion % 24 h 4 
Experiment 5 Cynomolgus 
monkeys 
T 0.5 h  2 µg/kg  30 min post-reperfusion    
Suzuki 2012b 33 Spr-Dawley rats T 2 h TAK-937 100 mcg/kg/h i.v. 2 h (on reperfusion) for 24 h mm3 24 h 2 
Teichner 2003 34 
Experiment 1-2 
 
Hypertensive rats 
 
P 
 
HU-211 
 
4.5 mg/kg 
 
i.v. 
 
1 h 
 
% 
 
1 and 30 
days 
 
4 
Zarruk 2012 41          
Experiment 1-3 Mice P JWH-133 0.5, 1.5 or 5 mg/kg i.p. 10 min post-onset % 48 h 6 
Experiment 4-5    1.5 mg/kg  10 min or 3 h post-onset    
Zhang 2007 43          
Experiment 1 and 3 Mice T 1 h O-3853 1 mg/kg i.v. 1 h pre- or 10 min post- mm3 24 h 3 
Experiment 2 and 4   O-1966 1 mg/kg  1 h pre- or 10 min post-    
Zhang 2008 11 
Experiment 1-2 
Experiment 3-4 
Experiment 5-6 
 
Mice 
 
T 1 h 
 
O-1966 
SR141716 
SR144528 
 
1 mg/kg 
5, 20 mg/kg 
5, 20 mg/kg 
 
i.v. 
 
1 h pre-onset 
 
% 
 
24 h 
 
2 
Zhang 2009 42          
Experiment 1-3 Mice T 1 h O-1966 1, 5, or 10 mg/kg i.p. 1 h pre-onset % 24 h 5 
Experiment 4-6    5 mg/kg  1 h pre-onset, 1 h or 3 h 
post-reperfusion 
   
Zhou 2012 44 
Experiement 1-9 
 
Kunming mice 
 
T 1.5 h 
 
OEA 
 
10, 20, 40 mg/kg 
 
oral 
3 d pre-onset or 30, 60, 90, 
150 min post onset 
 
mm3 
 
24 h 
 
5 
 *photothrombotic model; T, transient MCAO; P, permanent MCAO; PEA, palmitoylethanolamide; THC, Δ9-tetrahydrocannabinol; CBD, cannabidiol; OEA, oleoylethanolamide; i.p., intra-peritoneal; 
i.v., intravenous 
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Table 2. Change in infarct volume (according to stroke model, species and drug class), motor impairment and survival following administration of any 
cannabinoid in experimental stroke. 
 No of experiments No of animals  SMD [95% CI] P-value 
Lesion volume 
Stroke model     
Transient  90 945 -1.41 [-1.71, -1.11] < 0.00001 
Permanent 54 519 -1.67 [-2.08, -1.27] < 0.00001 
Species     
Rats 69 786 -1.75 [-2.15, -1.35] < 0.00001 
Mice 74 673 -1.34 [-1.61, -1.06] < 0.00001 
Monkeys 1 14 -0.55 [-1.63, 0.53] 0.32 
Drug Class     
Endocannabinoids 25 268 -1.72 [-2.62, -0.82] 0.0002 
Synthetic cannabinoids     
Mixed CB1/CB2 ligands 41 494 -1.75 [-2.19, -1.31] < 0.00001 
CB2 ligands 18 162 -1.65 [-2.09, -1.22] < 0.00001 
Abnormal CBD 2 16 -0.56 [-2.08, 0.95] 0.47 
HU-211 10 113 -2.90 [-4.24, -1.56] <0.0001 
CB1 antagonists 12 103 -0.70 [-1.22, -0.18] 0.009 
CB2 antagonists 2 14 0.96 [-0.32, 2.24] 0.14 
Phytocannbinoids     
THC 13 115 -1.43 [-2.01, -0.86] <0.00001 
CBD 21 188 -1.20 [-1.63, -0.77] <0.00001 
Motor Impairment 
Early (24-72hrs) neuro-score 55 590 -1.27 [-1.58, -0.95] <0.00001 
Late (2-4 weeks) neuro-score 8 126 -1.63 [-2.64, -0.62] 0.002 
Rotarod (24 hours post IS) 10 86 6.09 [0.7, 11.48]* 0.03 
Survival 
Transient ischaemia 7 154 2.09 (0.39, 11.3)† 0.39 
SMD, standardised mean difference; CI, confidence interval; * weighted mean difference (seconds); † odds ratio; IS, ischaemic stroke
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Figure 2 
Study or Subgroup
1.1.1 HU-210 (CB1/CB2 ligand)
Leker E1 2003 5mcg 1hr
Leker E2 2003 10mcg 1hr
Leker E3 2003 30mcg 1hr
Leker E4 2003 45mcg 1hr
Leker E5 2003 45mcg 1hr
Leker E6 2003 45mcg 2hr
Leker E7 2003 45mcg 4hr
Leker E8 2003 45mcg 6hr
Subtotal (95% CI)
Heterogeneity: Tau² = 4.70; Chi² = 27.87, df = 7 (P = 0.0002); I² = 75%
Test for overall effect: Z = 3.81 (P = 0.0001)
1.1.2 WIN 55,212-2 (CB1/CB2 ligand)
Bonfils 2006 9mg 0.5h
Hu 2010 1mg pre
Hu 2010 3mg pre
Hu 2010 5mg pre
Muthian E1 2004 0.1mg pre
Muthian E2 2004 0.3mg pre
Muthian E3 2004 1mg pre
Nagayama 1999 E1 1mg pre
Nagayama 1999 E2 1mg .5hr
Nagayama 1999 E3 1mg 1hr
Nagayama 1999 E4 1mg 2hr
Sun 2013a 1mg 2hr
Sun 2013a 9mg 2hr
Sun E1 2013 1mg 2h
Sun E2 2013 3mg 2h
Sun E3 2013 9mg 2h
Sun E4 2013 1mg 2h
Sun E5 2013 9mg 2h
Subtotal (95% CI)
Heterogeneity: Tau² = 1.48; Chi² = 41.67, df = 17 (P = 0.0007); I² = 59%
Test for overall effect: Z = 4.49 (P < 0.00001)
1.1.3 TAK-937 (CB1/CB2 ligand)
Murakami E1 2013 30µg 3h
Murakami E2 2013 100µg 3h
Murakami E3 2013 30µg 5h
Murakami E4 2013 100µg 5h
Murakami E5 2013 30µg 8h
Murakami E6 2013 100µg 8h
Murakami E7 2013 30µg 1h
Murakami E8 2013 100µg 1h
Murakami E9 2013 100µg 1h
Suzuki 2012 100µg 2hr
Suzuki 2012 10µg 2hr
Suzuki 2012 2µg 1hr
Suzuki 2012 30µg 2hr
Suzuki 2012 3µg 2hr
Suzuki 2012b 100µg 2h
Subtotal (95% CI)
Heterogeneity: Tau² = 0.57; Chi² = 35.06, df = 14 (P = 0.001); I² = 60%
Test for overall effect: Z = 5.40 (P < 0.00001)
1.1.4 JWH-133 (CB2 ligand)
Murikinati 2010 1mg pre
Zarruk E1 2012 0.5mg 10m
Zarruk E2 2012 1.5mg 10m
Zarruk E3 2012 5mg 10m
Zarruk E4 2012 1.5mg 10m
Zarruk E5 2012 1.5mg 3hr
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.06, df = 4 (P = 0.72); I² = 0%
Test for overall effect: Z = 3.51 (P = 0.0005)
1.1.5 O-3853 (CB2 ligand)
Zhang E1 2007 1mg pre
Zhang E3 2007 1mg 10m
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 3.22 (P = 0.001)
1.1.6 O-1966 (CB2 ligand)
Zhang E1 2008 1mg pre
Zhang E1 2009 1mg pre
Zhang E2 2007 1mg pre
Zhang E2 2008 1mg pre
Zhang E2 2009 5mg pre
Zhang E3 2009 10mg pre
Zhang E4 2007 1mg 10m
Zhang E4 2009 5mg pre
Zhang E5 2009 5mg 1hr
Zhang E6 2009 5mg 3hr
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 9.92, df = 9 (P = 0.36); I² = 9%
Test for overall effect: Z = 5.59 (P < 0.00001)
1.1.7 Abnormal CBD
Mishima 2005 E5 6mg pre
Mishima 2005 E6 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.73 (P = 0.47)
1.1.8 THC
Hayakawa 2004 E2 20mg pre
Hayakawa 2007a 20mg pre
Hayakawa 2007b E1 2mg pre
Hayakawa 2007b E2 6mg pre
Hayakawa 2007bE3 20mg pre
Hayakawa 2007c E4 2mg pre
Hayakawa 2007c E5 6mg pre
Hayakawa 2007cE15 20mg pr
Hayakawa 2007cE16 10mg pr
Hayakawa 2007cE17 10mg 3h
Hayakawa 2007cE18 10mg 4h
Hayakawa 2007cE6 20mg pre
Hayakawa 2007cE8 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 12.40, df = 12 (P = 0.41); I² = 3%
Test for overall effect: Z = 4.91 (P < 0.00001)
1.1.9 CBD
Hayakawa 2004 E1 6mg pre
Hayakawa 2007b E4 0.2mg
Hayakawa 2007b E5 2mg pre
Hayakawa 2007b E6 6mg pre
Hayakawa 2007c E1 0.2mg
Hayakawa 2007c E11 3mg 3h
Hayakawa 2007c E12 3mg 4h
Hayakawa 2007c E13 3mg 5h
Hayakawa 2007c E14 3mg 6h
Hayakawa 2007c E2 2mg pre
Hayakawa 2007c E3 6mg pre
Hayakawa 2007c E7 6mg pre
Hayakawa 2007c E9 6mg pre
Hayakawa 2007cE10 3mg pre
Hayakawa 2008 0.1mg pre
Hayakawa 2008 1mg pre
Hayakawa 2008 3mg pre
Mishima 2005 E1 0.2mg pre
Mishima 2005 E2 2mg pre
Mishima 2005 E3 6mg pre
Mishima 2005 E4 10mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 15.81, df = 20 (P = 0.73); I² = 0%
Test for overall effect: Z = 5.44 (P < 0.00001)
1.1.10 Anandamide
Mishima 2005 E7 6mg pre
Mishima 2005 E8 10mg pre
Schomacher 2008 E3 10mg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 2 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.07)
1.1.11 Methanandamide
Mishima 2005 E10 10mg pre
Mishima 2005 E9 6mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.87)
1.1.12 Palmitoylethanolamide
Ahmad 2012 10mg 1h
Garg 2010 10mg 0h
Garg 2010 10mg 2h
Garg 2010 10mg 3h
Garg 2010 10mg pre
Schomacher 2008 10mg 30m
Schomacher 2008 30mg 30m
Subtotal (95% CI)
Heterogeneity: Tau² = 13.36; Chi² = 70.45, df = 6 (P < 0.00001); I² = 91%
Test for overall effect: Z = 2.64 (P = 0.008)
1.1.13 Oleoylethanolamine
Sun 2007 10mg pre
Zhou 2012 E1 10mg pre
Zhou 2012 E2 20mg pre
Zhou 2012 E3 40mg pre
Zhou 2012 E4 40mg 0.5h
Zhou 2012 E5 40mg 1.5h
Zhou 2012 E6 40mg 1h
Zhou 2012 E7 40mg 2.5h
Zhou 2012 E8 10mg 1.5h
Zhou 2012 E9 40mg 1.5h
Subtotal (95% CI)
Heterogeneity: Tau² = 2.04; Chi² = 28.65, df = 9 (P = 0.0007); I² = 69%
Test for overall effect: Z = 4.10 (P < 0.0001)
1.1.14 Lauroylethanolamide
Garg E1 2011 10mg pre
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
1.1.15 Linoleoylethanolamide
Garg E2 2011 10mg pre
Garg E3 2011 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)
1.1.16 HU-211
Belayev 1995a 4mg 70min
Lavie 2001 E1 4.5mg 1hr
Lavie 2001 E2 4.5mg 3hr
Lavie 2001 E3 4.5mg 6hr
Lavie 2001 E4 4.5mg 1hr
Lavie 2001 E5 4.5mg 3hr
Lavie 2001 E6 4.5mg 6hr
Leker 1999 4mg 1hr
Teichner E1 2003 4.5mg 1h
Teichner E2 2003 4.5mg 1h
Subtotal (95% CI)
Heterogeneity: Tau² = 2.30; Chi² = 28.13, df = 9 (P = 0.0009); I² = 68%
Test for overall effect: Z = 4.23 (P < 0.0001)
1.1.17 SR141716 (CB1 antagonist)
Berger 2004 1mg 30min
Hayakawa 2007b E7 1mg pre
Hayakawa 2007cE19 1mg pre
Muthian E4 2004 0.3mg pre
Muthian E5 2004 1mg pre
Muthian E6 2004 3mg pre
Nagayama 1999 E5 1mg pre
Sun E6 2013 1mg 2h
Sun E7 2013 2mg 2h
Zhang E3 2008 5mg pre
Zhang E4 2008 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 12.20, df = 10 (P = 0.27); I² = 18%
Test for overall effect: Z = 2.33 (P = 0.02)
1.1.18 LY320153 (CB1 antagonist)
Muthian E7 2004 6mg pre
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
1.1.19 SR144528 (CB2 antagonist)
Zhang E5 2008 5mg pre
Zhang E6 2008 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI)
Heterogeneity: Tau² = 1.03; Chi² = 324.21, df = 142 (P < 0.00001); I² = 56%
Test for overall effect: Z = 12.24 (P < 0.00001)
Test for subgroup differences: Chi² = 48.72, df = 18 (P = 0.0001), I² = 63.1%
Mean
34.22
20.02
11.2
9.44
9.28
13.26
13.83
39.77
2.84
41.61
38.64
28.84
214.68
248.7
223.05
149.4
144.3
192.5
222.5
23.86
12.5
28.9
23.8
12.3
24.1
12.5
81.2
58.3
79.1
75.4
102.8
95.1
76.8
59.8
81.7
13.3
29.2
5.5
19.2
36.7
105.7
9.95
16.42
8.08
15.11
8.83
10.94
68.2
71.9
15.6
14.3
65.6
14.4
5.4
21.4
71.3
5.38
13.58
16.03
58.2
84.8
47.49
46.7
93.9
53.3
46.7
93.9
53.5
49
67
80
82.2
46.7
52.2
52.21
94.3
49.2
51.4
92.3
65.7
58.9
64.2
53
49.2
51.4
40.4
53
60.8
92.3
49.2
51.4
94.3
49.2
51.4
87
89.6
85.7
40.43
87.3
90.9
15.2
10.2
12.9
38.4
11.2
198.29
153.79
18
134.7
59.3
43.1
132.5
112.1
42
139
71.8
14.1
39.6
52.5
7.3
66.6
11.5
12
14.4
8.1
11.1
13.8
15.8
9.7
10
99
91.9
91.1
248.5
256
128.5
204.2
29.1
30.2
14.93
12.3
215
29.45
31.1
SD
4.32
9.17
3.62
4.5
4.92
3.98
5.49
10.04
2.59
5.65
8.92
2.69
95.9
47.2
100.33
20
9.2
10.8
10.8
2.58
2.3
3.04
4.29
2.14
2.5
2.3
10.6
21.9
14.2
11.7
19.3
25.4
10.5
11
17
7.2
13.2
3.4
11.2
10.3
64.8
3.82
2.61
4.43
5.86
4.35
3.26
14.1
17.3
3.73
4.41
11.3
3.69
3.67
9.55
15.6
2.35
2.2
6.79
32.3
28.04
15.39
13.4
18.6
23.3
17.7
26.3
29.4
16.7
31.2
11.4
10.5
16.7
22.8
15.39
36.3
30.9
20.6
23.5
10.6
27.8
14.8
19.6
25.3
19.3
34.1
18.8
20.6
21.5
23
21.9
34.2
29.2
20.6
35.4
26.4
22.8
13.36
37.6
20.4
0.62
0.9
3.5
5.4
2.3
54.75
53.13
2
74.4
24.8
30.1
87.3
69
35.6
52.8
15.4
19.2
4.16
36.9
11.8
51.5
0.02
3.2
2.4
0.6
2.3
2.5
1.7
4.7
6
41.6
4.75
8.2
40.2
98.4
100.6
32.6
5.6
3.1
3.35
1.93
44.7
5.88
5.48
Total
8
8
8
8
8
8
8
8
64
5
10
10
10
7
7
7
6
6
6
6
6
6
4
4
4
6
6
116
10
9
10
9
7
7
8
8
8
18
16
7
20
17
10
164
5
5
5
4
10
0
29
8
8
16
5
6
8
5
6
6
8
6
6
6
62
7
7
14
8
5
4
5
9
8
8
8
7
7
7
8
7
91
8
9
9
8
6
7
7
7
7
6
7
7
7
7
5
5
9
8
8
8
8
153
4
4
7
15
7
7
14
20
3
3
3
3
8
7
47
4
10
10
10
10
10
10
10
10
10
94
3
3
3
3
6
17
5
5
5
7
7
7
2
5
8
68
6
6
8
7
5
9
6
4
4
5
5
65
8
8
5
5
10
1039
Mean
39.86
39.86
39.86
39.86
39.77
39.77
39.77
39.77
12.43
50
50
50
260
260
260
211.7
211.7
211.7
211.7
31.2
31.2
32.1
32.1
32.1
31.2
31.2
100
100
100
100
100
100
100
100
100
38.3
38.3
8.1
38.3
38.3
272.8
15.98
18.37
18.37
18.37
16.58
16.58
99.2
99.8
22.4
25.1
99.2
23.55
25.1
25.1
99.8
24.74
24.74
24.74
92.3
92.3
91.36
91.3
91.3
91.3
91.3
91.3
91.3
93.3
93.3
93.3
93.3
91.3
85.5
91.36
91.3
91.3
91.3
91.3
94.6
94.6
94.6
94.6
91.3
91.3
85.5
94.6
94.6
91.3
91.3
91.3
91.3
91.3
91.3
91.3
92.3
92.3
57.21
92.3
92.3
35.1
38.4
38.4
38.4
38.4
223
236.23
27
189.7
189.7
189.7
172.4
172.4
172.4
172.4
175.6
175.6
38.1
38.1
38.1
149.8
20.8
20.8
20.8
24.49
24.49
24.49
22.1
20.75
24.4
164
91.3
91.3
260
260
260
211.7
32.1
32.1
23.55
24.7
260
23.55
24.7
SD
4.5
4.5
4.5
4.5
4.55
4.55
4.55
4.55
3.91
5.17
5.17
5.17
86
86
86
14.2
14.2
14.2
14.2
3.1
3.1
1.8
1.8
1.8
3.1
3.1
14.4
14.4
12.2
12.2
10.4
10.4
8.5
8.5
13.2
7.6
7.6
5.3
7.6
7.6
81
3.6
2.08
2.08
2.08
4.01
4.01
19.5
13
2.41
5.88
19.5
5.55
5.88
5.88
13
5.49
5.49
5.49
10.05
10.05
5.77
7.8
9.3
9.3
9.3
8.6
8.6
7.1
7.1
7.1
7.1
8.6
17.4
5.77
9.3
9.3
9.3
8.6
8.8
8.8
8.8
8.8
8.6
8.6
17.4
8.8
8.8
9.9
9.9
9.9
8.6
8.6
8.6
8.6
10.05
10.05
16.11
10.05
10.05
0.62
9.9
9.9
9.9
9.9
61.88
52.21
6.7
38.3
38.3
38.3
34.5
34.5
34.5
34.5
47.4
47.4
5.54
5.54
5.54
149.7
1.3
1.3
1.3
1.9
1.9
1.9
0.4
2.86
7.9
26.9
7
3.5
86
86
86
34.8
1.8
1.8
5.55
1.93
86
5.55
2.59
Total
2
2
2
2
2
2
2
2
16
5
3
3
3
4
4
4
2
1
1
1
3
3
1
1
1
3
3
46
9
9
4
4
4
4
4
4
9
5
5
7
5
5
10
88
5
2
2
1
5
5
20
4
4
8
5
2
4
2
2
2
4
2
2
2
27
1
1
2
3
5
1
1
1
1
1
2
2
2
2
1
2
24
4
1
1
1
1
1
1
1
1
1
1
3
2
2
3
3
2
2
2
1
1
35
1
1
11
13
2
1
3
20
1
1
1
1
10
11
45
5
2
2
2
2
2
2
2
3
3
25
1
1
1
1
2
17
2
2
2
2
2
2
3
5
8
45
6
1
2
4
3
3
1
1
1
2
3
27
3
3
2
2
4
434
Weight
0.8%
0.7%
0.3%
0.3%
0.3%
0.3%
0.5%
0.9%
4.2%
0.7%
0.9%
1.0%
0.4%
1.0%
1.0%
1.0%
0.6%
0.2%
0.6%
0.6%
0.7%
0.3%
0.6%
0.5%
0.1%
0.7%
0.3%
11.2%
1.1%
1.0%
1.0%
0.9%
1.0%
1.0%
0.9%
0.7%
1.1%
0.9%
1.1%
1.1%
1.1%
1.2%
1.1%
15.4%
0.9%
0.8%
0.6%
0.6%
1.0%
4.0%
0.9%
0.9%
1.9%
0.9%
0.7%
0.9%
0.6%
0.4%
0.9%
0.9%
0.3%
0.5%
0.8%
6.8%
0.7%
0.7%
1.3%
0.7%
0.6%
0.6%
0.6%
0.6%
0.7%
0.7%
0.7%
0.9%
0.8%
0.8%
0.5%
0.8%
9.0%
0.8%
0.7%
0.7%
0.6%
0.7%
0.5%
0.6%
0.6%
0.6%
0.6%
0.6%
0.9%
0.7%
0.8%
0.9%
0.7%
0.8%
0.9%
0.8%
0.6%
0.7%
14.8%
0.7%
0.6%
1.1%
2.4%
0.9%
0.7%
1.6%
0.1%
0.0%
0.0%
0.6%
0.0%
1.2%
1.1%
3.0%
0.9%
0.9%
0.5%
0.5%
0.9%
0.9%
0.6%
0.9%
0.6%
0.5%
7.2%
0.5%
0.5%
0.5%
0.1%
0.6%
1.3%
0.0%
0.5%
0.6%
0.1%
0.3%
0.5%
0.1%
0.8%
1.0%
5.2%
1.0%
0.7%
0.9%
1.0%
0.9%
0.9%
0.7%
0.6%
0.6%
0.6%
0.3%
8.3%
1.0%
1.0%
0.8%
0.8%
1.6%
100.0%
IV, Random, 95% CI
-1.17 [-2.86, 0.51]
-2.05 [-3.99, -0.12]
-6.92 [-11.11, -2.73]
-6.11 [-9.88, -2.34]
-5.65 [-9.19, -2.11]
-5.90 [-9.57, -2.24]
-4.35 [-7.25, -1.45]
0.00 [-1.55, 1.55]
-3.52 [-5.34, -1.71]
-2.61 [-4.54, -0.69]
-1.40 [-2.84, 0.04]
-1.26 [-2.68, 0.15]
-6.00 [-9.04, -2.95]
-0.45 [-1.70, 0.80]
-0.16 [-1.40, 1.07]
-0.35 [-1.59, 0.89]
-2.83 [-5.35, -0.31]
-6.17 [-11.50, -0.84]
-1.50 [-3.92, 0.93]
0.84 [-1.38, 3.06]
-2.38 [-4.40, -0.36]
-6.51 [-10.75, -2.27]
-0.77 [-3.19, 1.66]
-1.41 [-4.30, 1.49]
-6.73 [-16.05, 2.59]
-2.35 [-4.35, -0.35]
-6.51 [-10.75, -2.27]
-1.81 [-2.60, -1.02]
-1.43 [-2.47, -0.40]
-2.14 [-3.36, -0.93]
-1.43 [-2.74, -0.11]
-1.93 [-3.41, -0.46]
0.15 [-1.08, 1.38]
-0.21 [-1.44, 1.03]
-2.15 [-3.75, -0.56]
-3.60 [-5.73, -1.47]
-1.15 [-2.20, -0.10]
-3.31 [-4.76, -1.87]
-0.71 [-1.75, 0.32]
-0.55 [-1.62, 0.53]
-1.73 [-2.84, -0.62]
-0.16 [-1.16, 0.84]
-2.18 [-3.34, -1.03]
-1.38 [-1.88, -0.88]
-1.47 [-2.96, 0.02]
-0.65 [-2.37, 1.07]
-2.13 [-4.48, 0.22]
-0.40 [-2.66, 1.85]
-1.72 [-3.01, -0.43]
Not estimable
-1.35 [-2.10, -0.59]
-1.80 [-3.29, -0.31]
-1.60 [-3.03, -0.17]
-1.69 [-2.72, -0.66]
-1.96 [-3.61, -0.30]
-2.00 [-4.12, 0.11]
-2.17 [-3.78, -0.57]
-1.87 [-4.07, 0.34]
-4.16 [-7.43, -0.88]
-0.36 [-1.97, 1.26]
-1.77 [-3.25, -0.29]
-5.43 [-9.49, -1.37]
-3.22 [-5.96, -0.49]
-1.15 [-2.93, 0.64]
-1.87 [-2.53, -1.22]
-0.92 [-3.11, 1.27]
-0.23 [-2.33, 1.87]
-0.56 [-2.08, 0.95]
-2.90 [-4.91, -0.89]
-3.67 [-6.09, -1.26]
0.10 [-2.09, 2.30]
-1.30 [-3.79, 1.18]
-2.28 [-4.71, 0.16]
0.09 [-1.99, 2.17]
-1.14 [-3.34, 1.05]
-2.53 [-4.63, -0.42]
-0.81 [-2.45, 0.84]
-1.09 [-2.79, 0.62]
-0.98 [-2.66, 0.70]
-2.37 [-4.92, 0.17]
-1.34 [-3.11, 0.44]
-1.43 [-2.01, -0.86]
-2.73 [-4.52, -0.93]
0.07 [-1.99, 2.14]
-1.23 [-3.41, 0.95]
-1.72 [-4.06, 0.61]
0.04 [-2.08, 2.15]
-2.37 [-5.03, 0.28]
-1.12 [-3.35, 1.11]
-1.79 [-4.22, 0.64]
-1.85 [-4.30, 0.60]
-1.40 [-3.79, 0.99]
-1.80 [-4.23, 0.64]
-1.32 [-2.87, 0.22]
-2.09 [-4.12, -0.06]
-1.55 [-3.39, 0.29]
0.05 [-1.38, 1.48]
-1.86 [-3.79, 0.06]
-1.74 [-3.53, 0.04]
0.08 [-1.47, 1.63]
-1.38 [-3.12, 0.35]
-1.72 [-4.06, 0.61]
-0.11 [-2.19, 1.97]
-1.20 [-1.63, -0.77]
-0.07 [-2.27, 2.12]
-0.21 [-2.42, 2.00]
-1.06 [-2.08, -0.03]
-0.78 [-1.64, 0.08]
-0.13 [-1.70, 1.45]
-0.06 [-2.16, 2.04]
-0.10 [-1.36, 1.16]
-31.46 [-38.75, -24.17]
-17.90 [-119.23, 83.42]
-4.16 [-27.83, 19.50]
0.00 [-2.26, 2.26]
-6.76 [-45.06, 31.54]
-0.40 [-1.34, 0.54]
-1.49 [-2.59, -0.40]
-5.16 [-9.00, -1.32]
-1.53 [-3.15, 0.09]
-0.71 [-2.27, 0.85]
-4.55 [-7.24, -1.86]
-4.36 [-6.98, -1.75]
-0.44 [-1.97, 1.09]
-0.84 [-2.41, 0.73]
-3.39 [-5.64, -1.15]
-0.60 [-2.15, 0.94]
-3.93 [-6.16, -1.71]
-5.64 [-8.54, -2.74]
-2.29 [-3.38, -1.19]
0.21 [-2.34, 2.75]
0.21 [-2.34, 2.75]
0.22 [-2.37, 2.81]
-1.49 [-10.23, 7.25]
0.08 [-2.40, 2.57]
-0.73 [-1.42, -0.03]
-13.46 [-24.26, -2.67]
-2.54 [-5.13, 0.06]
-2.42 [-4.95, 0.10]
-16.05 [-26.06, -6.04]
-5.30 [-8.92, -1.67]
-3.92 [-6.80, -1.04]
-4.43 [-10.65, 1.80]
-2.57 [-4.47, -0.66]
-1.94 [-3.19, -0.69]
-2.90 [-4.24, -1.56]
-1.71 [-3.12, -0.31]
0.11 [-2.01, 2.23]
-0.02 [-1.57, 1.53]
-0.18 [-1.41, 1.06]
-0.04 [-1.47, 1.39]
-1.24 [-2.68, 0.20]
-0.19 [-2.32, 1.93]
-0.39 [-2.64, 1.86]
-0.45 [-2.72, 1.83]
-1.87 [-4.07, 0.34]
-5.59 [-9.69, -1.49]
-0.71 [-1.30, -0.11]
-0.73 [-2.11, 0.65]
-0.73 [-2.11, 0.65]
0.85 [-0.92, 2.63]
1.07 [-0.78, 2.92]
0.96 [-0.32, 2.24]
-1.49 [-1.73, -1.25]
Favours [experimental] Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours [experimental] Favours [control]
 
[30] 	
Study or Subgroup
1.1.1 HU-210 (CB1/CB2 ligand)
Leker E1 2003 5mcg 1hr
Leker E2 2003 10mcg 1hr
Leker E3 2003 30mcg 1hr
Leker E4 2003 45mcg 1hr
Leker E5 2003 45mcg 1hr
Leker E6 2003 45mcg 2hr
Leker E7 2003 45mcg 4hr
Leker E8 2003 45mcg 6hr
Subtotal (95% CI)
Heterogeneity: Tau² = 4.70; Chi² = 27.87, df = 7 (P = 0.0002); I² = 75%
Test for overall effect: Z = 3.81 (P = 0.0001)
1.1.2 WIN 55,212-2 (CB1/CB2 ligand)
Bonfils 2006 9mg 0.5h
Hu 2010 1mg pre
Hu 2010 3mg pre
Hu 2010 5mg pre
Muthian E1 2004 0.1mg pre
Muthian E2 2004 0.3mg pre
Muthian E3 2004 1mg pre
Nagayama 1999 E1 1mg pre
Nagayama 1999 E2 1mg .5hr
Nagayama 1999 E3 1mg 1hr
Nagayama 1999 E4 1mg 2hr
Sun 2013a 1mg 2hr
Sun 2013a 9mg 2hr
Sun E1 2013 1mg 2h
Sun E2 2013 3mg 2h
Sun E3 2013 9mg 2h
Sun E4 2013 1mg 2h
Sun E5 2013 9mg 2h
Subtotal (95% CI)
Heterogeneity: Tau² = 1.48; Chi² = 41.67, df = 17 (P = 0.0007); I² = 59%
Test for overall effect: Z = 4.49 (P < 0.00001)
1.1.3 TAK-937 (CB1/CB2 ligand)
Murakami E1 2013 30µg 3h
Murakami E2 2013 100µg 3h
Murakami E3 2013 30µg 5h
Murakami E4 2013 100µg 5h
Murakami E5 2013 30µg 8h
Murakami E6 2013 100µg 8h
Murakami E7 2013 30µg 1h
Murakami E8 2013 100µg 1h
Murakami E9 2013 100µg 1h
Suzuki 2012 100µg 2hr
Suzuki 2012 10µg 2hr
Suzuki 2012 2µg 1hr
Suzuki 2012 30µg 2hr
Suzuki 2012 3µg 2hr
Suzuki 2012b 100µg 2h
Subtotal (95% CI)
Heterogeneity: Tau² = 0.57; Chi² = 35.06, df = 14 (P = 0.001); I² = 60%
Test for overall effect: Z = 5.40 (P < 0.00001)
1.1.4 JWH-133 (CB2 ligand)
Murikinati 2010 1mg pre
Zarruk E1 2012 0.5mg 10m
Zarruk E2 2012 1.5mg 10m
Zarruk E3 2012 5mg 10m
Zarruk E4 2012 1.5mg 10m
Zarruk E5 2012 1.5mg 3hr
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.06, df = 4 (P = 0.72); I² = 0%
Test for overall effect: Z = 3.51 (P = 0.0005)
1.1.5 O-3853 (CB2 ligand)
Zhang E1 2007 1mg pre
Zhang E3 2007 1mg 10m
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 3.22 (P = 0.001)
1.1.6 O-1966 (CB2 ligand)
Zhang E1 2008 1mg pre
Zhang E1 2009 1mg pre
Zhang E2 2007 1mg pre
Zhang E2 2008 1mg pre
Zhang E2 2009 5mg pre
Zhang E3 2009 10mg pre
Zhang E4 2007 1mg 10m
Zhang E4 2009 5mg pre
Zhang E5 2009 5mg 1hr
Zhang E6 2009 5mg 3hr
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 9.92, df = 9 (P = 0.36); I² = 9%
Test for overall effect: Z = 5.59 (P < 0.00001)
1.1.7 Abnormal CBD
Mishima 2005 E5 6mg pre
Mishima 2005 E6 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.73 (P = 0.47)
1.1.8 THC
Hayakawa 2004 E2 20mg pre
Hayakawa 2007a 20mg pre
Hayakawa 2007b E1 2mg pre
Hayakawa 2007b E2 6mg pre
Hayakawa 2007bE3 20mg pre
Hayakawa 2007c E4 2mg pre
Hayakawa 2007c E5 6mg pre
Hayakawa 2007cE15 20mg pr
Hayakawa 2007cE16 10mg pr
Hayakawa 2007cE17 10mg 3h
Hayakawa 2007cE18 10mg 4h
Hayakawa 2007cE6 20mg pre
Hayakawa 2007cE8 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 12.40, df = 12 (P = 0.41); I² = 3%
Test for overall effect: Z = 4.91 (P < 0.00001)
1.1.9 CBD
Hayakawa 2004 E1 6mg pre
Hayakawa 2007b E4 0.2mg
Hayakawa 2007b E5 2mg pre
Hayakawa 2007b E6 6mg pre
Hayakawa 2007c E1 0.2mg
Hayakawa 2007c E11 3mg 3h
Hayakawa 2007c E12 3mg 4h
Hayakawa 2007c E13 3mg 5h
Hayakawa 2007c E14 3mg 6h
Hayakawa 2007c E2 2mg pre
Hayakawa 2007c E3 6mg pre
Hayakawa 2007c E7 6mg pre
Hayakawa 2007c E9 6mg pre
Hayakawa 2007cE10 3mg pre
Hayakawa 2008 0.1mg pre
Hayakawa 2008 1mg pre
Hayakawa 2008 3mg pre
Mishima 2005 E1 0.2mg pre
Mishima 2005 E2 2mg pre
Mishima 2005 E3 6mg pre
Mishima 2005 E4 10mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 15.81, df = 20 (P = 0.73); I² = 0%
Test for overall effect: Z = 5.44 (P < 0.00001)
1.1.10 Anandamide
Mishima 2005 E7 6mg pre
Mishima 2005 E8 10mg pre
Schomacher 2008 E3 10mg
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 2 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.07)
1.1.11 Methanandamide
Mishima 2005 E10 10mg pre
Mishima 2005 E9 6mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.87)
1.1.12 Palmitoylethanolamide
Ahmad 2012 10mg 1h
Garg 2010 10mg 0h
Garg 2010 10mg 2h
Garg 2010 10mg 3h
Garg 2010 10mg pre
Schomacher 2008 10mg 30m
Schomacher 2008 30mg 30m
Subtotal (95% CI)
Heterogeneity: Tau² = 13.36; Chi² = 70.45, df = 6 (P < 0.00001); I² = 91%
Test for overall effect: Z = 2.64 (P = 0.008)
1.1.13 Oleoylethanolamine
Sun 2007 10mg pre
Zhou 2012 E1 10mg pre
Zhou 2012 E2 20mg pre
Zhou 2012 E3 40mg pre
Zhou 2012 E4 40mg 0.5h
Zhou 2012 E5 40mg 1.5h
Zhou 2012 E6 40mg 1h
Zhou 2012 E7 40mg 2.5h
Zhou 2012 E8 10mg 1.5h
Zhou 2012 E9 40mg 1.5h
Subtotal (95% CI)
Heterogeneity: Tau² = 2.04; Chi² = 28.65, df = 9 (P = 0.0007); I² = 69%
Test for overall effect: Z = 4.10 (P < 0.0001)
1.1.14 Lauroylethanolamide
Garg E1 2011 10mg pre
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
1.1.15 Linoleoylethanolamide
Garg E2 2011 10mg pre
Garg E3 2011 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)
1.1.16 HU-211
Belayev 1995a 4mg 70min
Lavie 2001 E1 4.5mg 1hr
Lavie 2001 E2 4.5mg 3hr
Lavie 2001 E3 4.5mg 6hr
Lavie 2001 E4 4.5mg 1hr
Lavie 2001 E5 4.5mg 3hr
Lavie 2001 E6 4.5mg 6hr
Leker 1999 4mg 1hr
Teichner E1 2003 4.5mg 1h
Teichner E2 2003 4.5mg 1h
Subtotal (95% CI)
Heterogeneity: Tau² = 2.30; Chi² = 28.13, df = 9 (P = 0.0009); I² = 68%
Test for overall effect: Z = 4.23 (P < 0.0001)
1.1.17 SR141716 (CB1 antagonist)
Berger 2004 1mg 30min
Hayakawa 2007b E7 1mg pre
Hayakawa 2007cE19 1mg pre
Muthian E4 2004 0.3mg pre
Muthian E5 2004 1mg pre
Muthian E6 2004 3mg pre
Nagayama 1999 E5 1mg pre
Sun E6 2013 1mg 2h
Sun E7 2013 2mg 2h
Zhang E3 2008 5mg pre
Zhang E4 2008 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 12.20, df = 10 (P = 0.27); I² = 18%
Test for overall effect: Z = 2.33 (P = 0.02)
1.1.18 LY320153 (CB1 antagonist)
Muthian E7 2004 6mg pre
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
1.1.19 SR144528 (CB2 antagonist)
Zhang E5 2008 5mg pre
Zhang E6 2008 20mg pre
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI)
Heterogeneity: Tau² = 1.03; Chi² = 324.21, df = 142 (P < 0.00001); I² = 56%
Test for overall effect: Z = 12.24 (P < 0.00001)
Test for subgroup differences: Chi² = 48.72, df = 18 (P = 0.0001), I² = 63.1%
Mean
34.22
20.02
11.2
9.44
9.28
13.26
13.83
39.77
2.84
41.61
38.64
28.84
214.68
248.7
223.05
149.4
144.3
192.5
222.5
23.86
12.5
28.9
23.8
12.3
24.1
12.5
81.2
58.3
79.1
75.4
102.8
95.1
76.8
59.8
81.7
13.3
29.2
5.5
19.2
36.7
105.7
9.95
16.42
8.08
15.11
8.83
10.94
68.2
71.9
15.6
14.3
65.6
14.4
5.4
21.4
71.3
5.38
13.58
16.03
58.2
84.8
47.49
46.7
93.9
53.3
46.7
93.9
53.5
49
67
80
82.2
46.7
52.2
52.21
94.3
49.2
51.4
92.3
65.7
58.9
64.2
53
49.2
51.4
40.4
53
60.8
92.3
49.2
51.4
94.3
49.2
51.4
87
89.6
85.7
40.43
87.3
90.9
15.2
10.2
12.9
38.4
11.2
198.29
153.79
18
134.7
59.3
43.1
132.5
112.1
42
139
71.8
14.1
39.6
52.5
7.3
66.6
11.5
12
14.4
8.1
11.1
13.8
15.8
9.7
10
99
91.9
91.1
248.5
256
128.5
204.2
29.1
30.2
14.93
12.3
215
29.45
31.1
SD
4.32
9.17
3.62
4.5
4.92
3.98
5.49
10.04
2.59
5.65
8.92
2.69
95.9
47.2
100.33
20
9.2
10.8
10.8
2.58
2.3
3.04
4.29
2.14
2.5
2.3
10.6
21.9
14.2
11.7
19.3
25.4
10.5
11
17
7.2
13.2
3.4
11.2
10.3
64.8
3.82
2.61
4.43
5.86
4.35
3.26
14.1
17.3
3.73
4.41
11.3
3.69
3.67
9.55
15.6
2.35
2.2
6.79
32.3
28.04
15.39
13.4
18.6
23.3
17.7
26.3
29.4
16.7
31.2
11.4
10.5
16.7
22.8
15.39
36.3
30.9
20.6
23.5
10.6
27.8
14.8
19.6
25.3
19.3
34.1
18.8
20.6
21.5
23
21.9
34.2
29.2
20.6
35.4
26.4
22.8
13.36
37.6
20.4
0.62
0.9
3.5
5.4
2.3
54.75
53.13
2
74.4
24.8
30.1
87.3
69
35.6
52.8
15.4
19.2
4.16
36.9
11.8
51.5
0.02
3.2
2.4
0.6
2.3
2.5
1.7
4.7
6
41.6
4.75
8.2
40.2
98.4
100.6
32.6
5.6
3.1
3.35
1.93
44.7
5.88
5.48
Total
8
8
8
8
8
8
8
8
64
5
10
10
10
7
7
7
6
6
6
6
6
6
4
4
4
6
6
116
10
9
10
9
7
7
8
8
8
18
16
7
20
17
10
164
5
5
5
4
10
0
29
8
8
16
5
6
8
5
6
6
8
6
6
6
62
7
7
14
8
5
4
5
9
8
8
8
7
7
7
8
7
91
8
9
9
8
6
7
7
7
7
6
7
7
7
7
5
5
9
8
8
8
8
153
4
4
7
15
7
7
14
20
3
3
3
3
8
7
47
4
10
10
10
10
10
10
10
10
10
94
3
3
3
3
6
17
5
5
5
7
7
7
2
5
8
68
6
6
8
7
5
9
6
4
4
5
5
65
8
8
5
5
10
1039
Mean
39.86
39.86
39.86
39.86
39.77
39.77
39.77
39.77
12.43
50
50
50
260
260
260
211.7
211.7
211.7
211.7
31.2
31.2
32.1
32.1
32.1
31.2
31.2
100
100
100
100
100
100
100
100
100
38.3
38.3
8.1
38.3
38.3
272.8
15.98
18.37
18.37
18.37
16.58
16.58
99.2
99.8
22.4
25.1
99.2
23.55
25.1
25.1
99.8
24.74
24.74
24.74
92.3
92.3
91.36
91.3
91.3
91.3
91.3
91.3
91.3
93.3
93.3
93.3
93.3
91.3
85.5
91.36
91.3
91.3
91.3
91.3
94.6
94.6
94.6
94.6
91.3
91.3
85.5
94.6
94.6
91.3
91.3
91.3
91.3
91.3
91.3
91.3
92.3
92.3
57.21
92.3
92.3
35.1
38.4
38.4
38.4
38.4
223
236.23
27
189.7
189.7
189.7
172.4
172.4
172.4
172.4
175.6
175.6
38.1
38.1
38.1
149.8
20.8
20.8
20.8
24.49
24.49
24.49
22.1
20.75
24.4
164
91.3
91.3
260
260
260
211.7
32.1
32.1
23.55
24.7
260
23.55
24.7
SD
4.5
4.5
4.5
4.5
4.55
4.55
4.55
4.55
3.91
5.17
5.17
5.17
86
86
86
14.2
14.2
14.2
14.2
3.1
3.1
1.8
1.8
1.8
3.1
3.1
14.4
14.4
12.2
12.2
10.4
10.4
8.5
8.5
13.2
7.6
7.6
5.3
7.6
7.6
81
3.6
2.08
2.08
2.08
4.01
4.01
19.5
13
2.41
5.88
19.5
5.55
5.88
5.88
13
5.49
5.49
5.49
10.05
10.05
5.77
7.8
9.3
9.3
9.3
8.6
8.6
7.1
7.1
7.1
7.1
8.6
17.4
5.77
9.3
9.3
9.3
8.6
8.8
8.8
8.8
8.8
8.6
8.6
17.4
8.8
8.8
9.9
9.9
9.9
8.6
8.6
8.6
8.6
10.05
10.05
16.11
10.05
10.05
0.62
9.9
9.9
9.9
9.9
61.88
52.21
6.7
38.3
38.3
38.3
34.5
34.5
34.5
34.5
47.4
47.4
5.54
5.54
5.54
149.7
1.3
1.3
1.3
1.9
1.9
1.9
0.4
2.86
7.9
26.9
7
3.5
86
86
86
34.8
1.8
1.8
5.55
1.93
86
5.55
2.59
Total
2
2
2
2
2
2
2
2
16
5
3
3
3
4
4
4
2
1
1
1
3
3
1
1
1
3
3
46
9
9
4
4
4
4
4
4
9
5
5
7
5
5
10
88
5
2
2
1
5
5
20
4
4
8
5
2
4
2
2
2
4
2
2
2
27
1
1
2
3
5
1
1
1
1
1
2
2
2
2
1
2
24
4
1
1
1
1
1
1
1
1
1
1
3
2
2
3
3
2
2
2
1
1
35
1
1
11
13
2
1
3
20
1
1
1
1
10
11
45
5
2
2
2
2
2
2
2
3
3
25
1
1
1
1
2
17
2
2
2
2
2
2
3
5
8
45
6
1
2
4
3
3
1
1
1
2
3
27
3
3
2
2
4
434
Weight
0.8%
0.7%
0.3%
0.3%
0.3%
0.3%
0.5%
0.9%
4.2%
0.7%
0.9%
1.0%
0.4%
1.0%
1.0%
1.0%
0.6%
0.2%
0.6%
0.6%
0.7%
0.3%
0.6%
0.5%
0.1%
0.7%
0.3%
11.2%
1.1%
1.0%
1.0%
0.9%
1.0%
1.0%
0.9%
0.7%
1.1%
0.9%
1.1%
1.1%
1.1%
1.2%
1.1%
15.4%
0.9%
0.8%
0.6%
0.6%
1.0%
4.0%
0.9%
0.9%
1.9%
0.9%
0.7%
0.9%
0.6%
0.4%
0.9%
0.9%
0.3%
0.5%
0.8%
6.8%
0.7%
0.7%
1.3%
0.7%
0.6%
0.6%
0.6%
0.6%
0.7%
0.7%
0.7%
0.9%
0.8%
0.8%
0.5%
0.8%
9.0%
0.8%
0.7%
0.7%
0.6%
0.7%
0.5%
0.6%
0.6%
0.6%
0.6%
0.6%
0.9%
0.7%
0.8%
0.9%
0.7%
0.8%
0.9%
0.8%
0.6%
0.7%
14.8%
0.7%
0.6%
1.1%
2.4%
0.9%
0.7%
1.6%
0.1%
0.0%
0.0%
0.6%
0.0%
1.2%
1.1%
3.0%
0.9%
0.9%
0.5%
0.5%
0.9%
0.9%
0.6%
0.9%
0.6%
0.5%
7.2%
0.5%
0.5%
0.5%
0.1%
0.6%
1.3%
0.0%
0.5%
0.6%
0.1%
0.3%
0.5%
0.1%
0.8%
1.0%
5.2%
1.0%
0.7%
0.9%
1.0%
0.9%
0.9%
0.7%
0.6%
0.6%
0.6%
0.3%
8.3%
1.0%
1.0%
0.8%
0.8%
1.6%
100.0%
IV, Random, 95% CI
-1.17 [-2.86, 0.51]
-2.05 [-3.99, -0.12]
-6.92 [-11.11, -2.73]
-6.11 [-9.88, -2.34]
-5.65 [-9.19, -2.11]
-5.90 [-9.57, -2.24]
-4.35 [-7.25, -1.45]
0.00 [-1.55, 1.55]
-3.52 [-5.34, -1.71]
-2.61 [-4.54, -0.69]
-1.40 [-2.84, 0.04]
-1.26 [-2.68, 0.15]
-6.00 [-9.04, -2.95]
-0.45 [-1.70, 0.80]
-0.16 [-1.40, 1.07]
-0.35 [-1.59, 0.89]
-2.83 [-5.35, -0.31]
-6.17 [-11.50, -0.84]
-1.50 [-3.92, 0.93]
0.84 [-1.38, 3.06]
-2.38 [-4.40, -0.36]
-6.51 [-10.75, -2.27]
-0.77 [-3.19, 1.66]
-1.41 [-4.30, 1.49]
-6.73 [-16.05, 2.59]
-2.35 [-4.35, -0.35]
-6.51 [-10.75, -2.27]
-1.81 [-2.60, -1.02]
-1.43 [-2.47, -0.40]
-2.14 [-3.36, -0.93]
-1.43 [-2.74, -0.11]
-1.93 [-3.41, -0.46]
0.15 [-1.08, 1.38]
-0.21 [-1.44, 1.03]
-2.15 [-3.75, -0.56]
-3.60 [-5.73, -1.47]
-1.15 [-2.20, -0.10]
-3.31 [-4.76, -1.87]
-0.71 [-1.75, 0.32]
-0.55 [-1.62, 0.53]
-1.73 [-2.84, -0.62]
-0.16 [-1.16, 0.84]
-2.18 [-3.34, -1.03]
-1.38 [-1.88, -0.88]
-1.47 [-2.96, 0.02]
-0.65 [-2.37, 1.07]
-2.13 [-4.48, 0.22]
-0.40 [-2.66, 1.85]
-1.72 [-3.01, -0.43]
Not estimable
-1.35 [-2.10, -0.59]
-1.80 [-3.29, -0.31]
-1.60 [-3.03, -0.17]
-1.69 [-2.72, -0.66]
-1.96 [-3.61, -0.30]
-2.00 [-4.12, 0.11]
-2.17 [-3.78, -0.57]
-1.87 [-4.07, 0.34]
-4.16 [-7.43, -0.88]
-0.36 [-1.97, 1.26]
-1.77 [-3.25, -0.29]
-5.43 [-9.49, -1.37]
-3.22 [-5.96, -0.49]
-1.15 [-2.93, 0.64]
-1.87 [-2.53, -1.22]
-0.92 [-3.11, 1.27]
-0.23 [-2.33, 1.87]
-0.56 [-2.08, 0.95]
-2.90 [-4.91, -0.89]
-3.67 [-6.09, -1.26]
0.10 [-2.09, 2.30]
-1.30 [-3.79, 1.18]
-2.28 [-4.71, 0.16]
0.09 [-1.99, 2.17]
-1.14 [-3.34, 1.05]
-2.53 [-4.63, -0.42]
-0.81 [-2.45, 0.84]
-1.09 [-2.79, 0.62]
-0.98 [-2.66, 0.70]
-2.37 [-4.92, 0.17]
-1.34 [-3.11, 0.44]
-1.43 [-2.01, -0.86]
-2.73 [-4.52, -0.93]
0.07 [-1.99, 2.14]
-1.23 [-3.41, 0.95]
-1.72 [-4.06, 0.61]
0.04 [-2.08, 2.15]
-2.37 [-5.03, 0.28]
-1.12 [-3.35, 1.11]
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Figure 3 
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